LUMOS PHARMA, INC.
LUMOHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $2.1M | $1.5M | $230,000 | $168,000 | $936,000 | $1.2M |
| Operating income | −$36.6M | −$32.0M | −$31.3M | −$26.3M | −$9.8M | −$18.7M |
| Net income | −$34.0M | −$31.1M | −$30.4M | −$5.7M | −$9.7M | −$18.3M |
| Total assets | $40.6M | $72.3M | $100.3M | $129.0M | $5.5M | $130.9M |
| Total liabilities | $13.3M | $12.7M | $11.3M | $12.5M | $1.5M | $15.8M |
| Equity | $27.3M | $59.6M | $89.0M | $116.6M | −$59.5M | −$46.9M |
| EPS (diluted) | $-4.18 | $-3.71 | $-3.65 | $-0.93 | $-0.27 | $-0.49 |
| Shares out. | 8.2M | 8.4M | 8.3M | 37.3M | 37.3M | 37.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −1785.2%
- Net margin
- −1659.4%
- Return on equity
- −124.6%
- Return on assets
- −83.7%
- Return on capital (ROCE)
- −108.9%
- Liabilities / assets
- 32.8%
- Debt / equity
- 0.49×
- Book value / share
- $3.32
- Revenue growth (YoY)
- 34.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -11.53distress
- Accruals / assets
- −7.2%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Recruitingreadout ~2027-12Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
- Phase 2Enrolling By Invitationreadout ~2028-03A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)
- Phase 3Not Yet Recruitingreadout ~2030-02Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency
- Phase 2Active Not Recruitingreadout ~2030-04PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Private Advisor Group, LlcPassive (13G)Feb 13, 2025
- Goldman Sachs Group IncPassive (13G)Feb 13, 2025
- Wells Fargo & Company/MnPassive (13G)Oct 25, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventDec 12, 2024
- Delisting / listing-standard notice · Other material eventNov 25, 2024
- Entered a material agreement · Results of operations · New financial obligationOct 23, 2024
- Results of operationsAug 1, 2024
- Shareholder vote · Regulation FD disclosureJun 5, 2024
- Results of operationsMay 15, 2024
- Other material eventApr 18, 2024
- Other material eventMar 20, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.